Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Accumulated Expenses: 2023-2024

Historic Accumulated Expenses for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $39.4 million.

  • Zenas BioPharma's Accumulated Expenses rose 58.98% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.4 million, marking a year-over-year increase of 58.98%. This contributed to the annual value of $39.4 million for FY2024, which is 127.50% up from last year.
  • Latest data reveals that Zenas BioPharma reported Accumulated Expenses of $39.4 million as of FY2024, which was up 127.50% from $17.3 million recorded in FY2023.
  • In the past 5 years, Zenas BioPharma's Accumulated Expenses ranged from a high of $39.4 million in FY2024 and a low of $17.3 million during FY2023.
  • Its 2-year average for Accumulated Expenses is $28.3 million, with a median of $28.3 million in 2023.
  • Data for Zenas BioPharma's Accumulated Expenses shows a peak YoY surged of 127.50% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's Accumulated Expenses (Yearly) stood at $17.3 million in 2023, then surged by 127.50% to $39.4 million in 2024.